UBC: Lactation drug cabergoline shows promise to lower postpartum breast cancer risk

Investigators found cabergoline — a drug used clinically to suppress lactation — appears to accelerate breast involution after weaning, reducing potentially precancerous tissue, shrinking ductal area, lowering cell proliferation and boosting immune clearance in mice. Building on these findings, the team secured Gray Foundation funding for a multinational clinical trial: after weaning, women with a BRCA1 mutation recruited through high‑risk clinics will receive cabergoline or placebo and be monitored for biological markers linked to future breast cancer risk. Cabergoline already holds regulatory approval in Canada and the EU.